Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 5/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 5/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.37 |
| ▸ | TACR1 | P25103 | 9/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3655376 | 0.77 | PRSS1 (0.65) | PRSS1PRSS2PRSS3NPY5R | |
| SCHEMBL2913163 | 0.75 | PRSS1 (0.48) | PRSS1PRSS2PRSS3NPY5R | |
| SCHEMBL2911159 | 0.74 | PRSS1 (0.85) | PRSS1PRSS2PRSS3NPY5R | |
| SCHEMBL2921980 | 0.74 | PRSS1 (0.49) | PRSS1PRSS2PRSS3NPY5RTACR1 | |
| SCHEMBL10287950 | 0.73 | PRSS1 (0.39) | PRSS1PRSS2PRSS3NPY5RTACR1 | |
| SCHEMBL3662216 | 0.69 | PRSS1 (0.65) | PRSS1PRSS2PRSS3NPY5R | |
| SCHEMBL8047634 | 0.68 | NPY5R (0.33) | PRSS1PRSS2PRSS3NPY5R | |
| SCHEMBL3661866 | 0.68 | PRSS1 (0.64) | PRSS1PRSS2PRSS3NPY5RTACR1 | |
| SCHEMBL14242298 | 0.68 | NPY5R (0.56) | NPY5RTACR1 | |
| SCHEMBL3661046 | 0.67 | PRSS1 (0.74) | PRSS1PRSS2PRSS3NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | disclosed |
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | PRSS1 7/4885PRSS2 33/4885PRSS3 9/4885 |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | TPSAB1, TPSB2, TPSD1 | PRSS1 7/4885PRSS2 33/4885PRSS3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.